GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Net Income (Discontinued Operations)

Aclaris Therapeutics (FRA:8AT) Net Income (Discontinued Operations) : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Aclaris Therapeutics's Net Income (Discontinued Operations) for the three months ended in Mar. 2024 was €0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Aclaris Therapeutics Net Income (Discontinued Operations) Historical Data

The historical data trend for Aclaris Therapeutics's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Net Income (Discontinued Operations) Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.03 0.11 - - -

Aclaris Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aclaris Therapeutics Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (FRA:8AT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
ME CDNA CSTL LDDD NVTA LAB BDSX GTH BNR FONR TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
ACRS:USA
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Website
https://www.aclaristx.com
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines